Expand FULC Menu
FULC MENU

FULC Latest Press Releases

-- June 9, 2026 --

Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 9:00 AM

-- June 5, 2026 --

Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC) Globe Newswire 9:00 AM

-- June 4, 2026 --

FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud Business Wire 2:53 PM

-- June 3, 2026 --

FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations PRNewswire 9:00 AM

-- June 2, 2026 --

Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) PRNewswire 5:07 PM
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses Globe Newswire 12:56 PM
FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc. Globe Newswire 11:37 AM

-- June 1, 2026 --

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review Globe Newswire 4:05 PM

-- May 8, 2026 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- April 27, 2026 --

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 Globe Newswire 7:00 AM
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors Globe Newswire 6:55 AM

-- April 20, 2026 --

Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET Globe Newswire 8:00 AM

-- March 19, 2026 --

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease Globe Newswire 8:00 AM

-- March 6, 2026 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- March 3, 2026 --

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference Globe Newswire 8:30 AM

-- February 24, 2026 --

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 Globe Newswire 7:01 AM
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Globe Newswire 7:00 AM

-- February 17, 2026 --

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Globe Newswire 8:00 AM

-- February 6, 2026 --

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes